Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962190 | 0.91 | ROCK2 (0.51) | ROCK2ROCK1TRPV1NAMPTCYP2C9 | |
| SCHEMBL961709 | 0.86 | ROCK2 (0.53) | ROCK2ROCK1TRPV1CYP2C9MEN1 | |
| SCHEMBL966362 | 0.85 | ROCK2 (0.49) | ROCK2ROCK1TRPV1NAMPTCYP2C9 | |
| SCHEMBL964090 | 0.85 | ATG4B (0.47) | ROCK2ROCK1TRPV1NAMPTCYP2C9 | |
| SCHEMBL965634 | 0.85 | ROCK2 (0.49) | ROCK2ROCK1NAMPTCYP2C9DGAT2 | |
| SCHEMBL962477 | 0.83 | NPC1 (0.50) | KDM4CROCK2ROCK1NAMPTCYP2C9 | |
| SCHEMBL965409 | 0.82 | IMPDH2 (0.49) | ROCK2ROCK1TRPV1NAMPTMEN1 | |
| SCHEMBL963778 | 0.81 | ROCK2 (0.53) | ROCK2ROCK1TRPV1NAMPTNPC1 | |
| SCHEMBL964600 | 0.80 | ROCK2 (0.49) | ROCK2ROCK1TRPV1NAMPTMEN1 | |
| SCHEMBL966705 | 0.80 | NAMPT (0.44) | ROCK2ROCK1TRPV1NAMPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501769-B2 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | claimed |
| US-7875627-B2 | e.g.1-(4-Chloro-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea; 2-Methyl-thieno[2,3-c]pyridin-3-yl)-carbamic acid 4-trifluoromethylsulfanyl-benzyl ester; controlling pain, urinary incontinence, bladder overactivity, and inflammatory thermal hyperalgesia in mammals | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | claimed |
| US-20060148843-A1 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. | 2006-07-06 | — | — | US | claimed |
| US-8501769-B2 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110082170-A1 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-04-07 | — | — | US | disclosed |
| US-7875627-B2 | e.g.1-(4-Chloro-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea; 2-Methyl-thieno[2,3-c]pyridin-3-yl)-carbamic acid 4-trifluoromethylsulfanyl-benzyl ester; controlling pain, urinary incontinence, bladder overactivity, and inflammatory thermal hyperalgesia in mammals | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| US-20060148843-A1 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148843-A1 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | TRPV1, GPR55, P2RX6 | KDM4C 2494/4885ROCK2 2602/4885ROCK1 1181/4885 |
| US-20110082170-A1 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | TRPV1, GPR55, P2RX6 | KDM4C 2494/4885ROCK2 2602/4885ROCK1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.